Publications by authors named "Pierre Johansen"

Claim this Profile
I
Impact of systemic inflammation on healthcare resource utilization and cost in patients with atherosclerotic cardiovascular disease and chronic kidney disease.
Jan Håkon Rudolfsen, Jelena Vukmirica, Pierre Johansen, Kasper Løwe Røder, Martin Bødtker Mortensen

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic inflammation prevalence in patients with atherosclerotic cardiovascular disease and chronic kidney disease: a population-based study using a nationwide primary care database in Spain.
Giancarlo Pesce, Gaelle Gusto, Pierre Johansen, Artak Khachatryan, Bernabe Lopez-Ledesma

Front Cardiovasc Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prevalence of comorbidities in Danish patients with obesity - A Danish register-based study based on data from 2002 to 2018.
Mikkel H Pedersen, Mette Bøgelund, Carsten Dirksen, Pierre Johansen, Nils B Jørgensen

Clin Obes· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
Zobair Younossi, Priya Aggarwal, Ichhya Shrestha, João Fernandes, Pierre Johansen

JHEP Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
Michal Witkowski, Søren Ilsøe Moreno, João Fernandes, Pierre Johansen, Margarida Augusto

Pharmacoeconomics· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The substantial costs to society associated with obesity - a Danish register-based study based on 2002-2018 data.
Maria Spanggaard, Mette Bøgelund, Carsten Dirksen, Nils Bruun Jørgensen, Steen Madsbad, Pierre Johansen

Expert Rev Pharmacoecon Outcomes Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies.
Elliot B Tapper, Charlotte Fleming, Adriana Rendon, João Fernandes, Pierre Johansen

Gastro Hep Adv· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Bariatric Surgery on Healthcare Costs and Labor Market Attachment.
Mette Bøgelund, Nils B Jørgensen, Sten Madsbad, Maria Spanggaard, Ulrik H Panton, Pierre Johansen

Obes Surg· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.
Lyndon Marc Evans, Linda Mellbin, Pierre Johansen, Jack Lawson, Abby Paine

Endocrinol Diabetes Metab· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Authors' reply to Comment on "External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions".
Sandra Lopes, Pierre Johansen, Mark Lamotte, Phil McEwan, Anamaria-Vera Olivieri

Pharmacoeconomics· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
Ildiko Lingvay, Matthew S Capehorn, Andrei-Mircea Catarig, Pierre Johansen, Jack Lawson

J Clin Endocrinol Metab· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions.
Sandra Lopes, Pierre Johansen, Mark Lamotte, Phil McEwan, Anamaria-Vera Olivieri

Pharmacoeconomics· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden.
Sofie Persson, Pierre Johansen, Emelie Andersson, Peter Lindgren, Desirée Thielke

Diabetes Obes Metab· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM.
Michael Willis, Adam Fridhammar, Jens Gundgaard, Andreas Nilsson, Pierre Johansen

Pharmacoeconomics· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.
Pierre Johansen, Daniel Howard, Ryan Bishop, Søren Ilsøe Moreno, Kristine Buchholtz

Pharmacoeconomics· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-Weekly Semaglutide Reduces HbA and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10.
Matthew Capehorn, Yasmin Ghani, Charlotte Hindsberger, Pierre Johansen, Esteban Jódar

Diabetes Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Pierre Johansen, Barrie Chubb, Barnaby Hunt, Samuel J P Malkin, Anna Sandberg

Adv Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
Pierre Johansen, Anna Sandberg, Matthew Capehorn

Adv Ther· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.
Pierre Johansen, Jonas Håkan-Bloch, Aiden R Liu, Peter G Bech, Sofie Persson

Pharmacoecon Open· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Peter Gæde, Pierre Johansen, Christian Klyver Tikkanen, Richard Fulton Pollock, Barnaby Hunt

Diabetes Ther· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
Peter Gæde, Pierre Johansen, Christian Klyver Tikkanen, Richard Fulton Pollock, Barnaby Hunt

Diabetes Ther· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India.
Vishal Gupta, Michael Willis, Pierre Johansen, Andreas Nilsson, Manan Shah

Value Health Reg Issues· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Pierre Johansen, Barnaby Hunt, Neeraj N Iyer, Tam Dang-Tan, Richard F Pollock

Adv Ther· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA.
Pierre Johansen, Barnaby Hunt, Neeraj N Iyer, Tam Dang-Tan, Richard F Pollock

Adv Ther· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Adie Viljoen, Christina S Hoxer, Pierre Johansen, Samuel Malkin, Barnaby Hunt

Diabetes Obes Metab· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis